

Florent Mouliere

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/977712/florent-mouliere-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42
papers

4,201
citations

20
h-index

58
g-index

58
ext. papers

5,368
ext. citations

9.3
avg, IF

5.46
L-index

#	Paper	IF	Citations
42	Refined characterization of circulating tumor DNA through biological feature integration.. <i>Scientific Reports</i> , 2022 , 12, 1928	4.9	2
41	Circulating tumor DNA (ctDNA) analysis by low-coverage whole genome sequencing (lcWGS) of resectable esophageal adenocarcinoma (rEAC) patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4033-4033 ^{2,2}		
40	Fragmentation patterns and personalized sequencing of cell-free DNA in urine and plasma of glioma patients. <i>EMBO Molecular Medicine</i> , 2021 , 13, e12881	12	15
39	PCR-Free Shallow Whole Genome Sequencing for Chromosomal Copy Number Detection from Plasma of Cancer Patients Is an Efficient Alternative to the Conventional PCR-Based Approach. <i>Journal of Molecular Diagnostics</i> , 2021 , 23, 1553-1563	5.1	0
38	Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA.. <i>Genome Research</i> , 2021 ,	9.7	2
37	ctDNA monitoring using patient-specific sequencing and integration of variant reads. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	57
36	Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. <i>Genome Medicine</i> , 2020 , 12, 23	14.4	37
35	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations. <i>PLoS ONE</i> , 2020 , 15, e0231884	3.7	5
34	Cell-Free DNA Fragmentomics: The New "Omics" on the Block. <i>Clinical Chemistry</i> , 2020 , 66, 1480-1484	5.5	4
33	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients Initial observations 2020 , 15, e0231884		
32	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients Initial observations 2020 , 15, e0231884		
31	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients Initial observations 2020 , 15, e0231884		
30	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients Initial observations 2020 , 15, e0231884		
29	Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. <i>Cancer Cell</i> , 2019 , 36, 350-368	24.3	90
28	Measurement of Plasma Cell-Free Mitochondrial Tumor DNA Improves Detection of Glioblastoma in Patient-Derived Orthotopic Xenograft Models. <i>Cancer Research</i> , 2019 , 79, 220-230	10.1	44
27	The value of cell-free DNA for molecular pathology. <i>Journal of Pathology</i> , 2018 , 244, 616-627	9.4	62
26	Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. <i>Oncotarget</i> , 2018 , 9, 32570-32579	3.3	12

25	Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	71
24	Enhanced detection of circulating tumor DNA by fragment size analysis. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	350
23	Liquid biopsies come of age: towards implementation of circulating tumour DNA. <i>Nature Reviews Cancer</i> , 2017 , 17, 223-238	31.3	1192
22	Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. <i>Scientific Reports</i> , 2017 , 7, 5554	4.9	51
21	A pilot study of individualised monitoring of patients with metastatic melanoma using plasma and urine DNA.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21032-e21032	2.2	
20	Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. <i>Clinical Cancer Research</i> , 2016 , 22, 3067-77	12.9	110
19	CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11530-11530	2.2	
18	A phylogenetic latent feature model for clonal deconvolution. <i>Annals of Applied Statistics</i> , 2016 , 10,	2.1	31
17	Detection of Genetic Alterations by Nucleic Acid Analysis: Use of PCR and Mass Spectroscopy-Based Methods. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015 , 89-111 ^{0.4}		1
16	Circulating tumor-derived DNA is shorter than somatic DNA in plasma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 3178-9	11.5	98
15	Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. <i>Molecular Oncology</i> , 2014 , 8, 927-41	7.9	145
14	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. <i>Nature Medicine</i> , 2014 , 20, 430-5	50.5	474
13	Circulating DNA as a strong multimarker prognostic tool in metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3604-3604	2.2	
12	Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. <i>Translational Oncology</i> , 2013 , 6, 319-28	4.9	125
11	Circulating cell free DNA: Preanalytical considerations. <i>Clinica Chimica Acta</i> , 2013 , 424, 222-30	6.2	365
10	Personalized Medicine by Analyzing Circulating DNA: Application to the Management Care of Colorectal Cancer Patients. <i>Annals of Oncology</i> , 2013 , 24, i7	10.3	2
9	P3.12 Circulating Dna Analysis in The Era of Personalized Cancer Medicine: Application to Kras/Braf Point Mutations Detection in Colorectal Cancer. <i>Annals of Oncology</i> , 2012 , 23, v36-v37	10.3	1
8	The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12 Suppl 1, S209-15	5.4	58

7	Circulating DNA analysis and concordance with tumor section analysis in the detection of KRAS and BRAF point mutations from metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10505-10505	2,2	3
6	High fragmentation characterizes tumour-derived circulating DNA. <i>PLoS ONE</i> , 2011 , 6, e23418	3.7	337
5	Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. <i>Nucleic Acids Research</i> , 2010 , 38, 6159-75	20.1	207
4	Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. <i>Neurobiology of Disease</i> , 2008 , 31, 316-26	7.5	232
3	Selecting short DNA fragments in plasma improves detection of circulating tumour DNA		8
2	Integrated clonal analysis reveals circulating tumor DNA in urine and plasma of glioma patients		1
1	High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads		4